28th Jan 2026 16:12
BICO Group AB (publ) ("BICO" or the "Company") has successfully issued senior secured bonds in the total nominal of EUR 40 million under a framework amount of EUR 60 million (the "Bonds"). The Bonds have a tenor of four years and carry a floating interest rate of three-month EURIBOR plus a margin of 5.90 per cent. The Bonds were issued at 96.81 per cent of par. The net proceeds from the bond issue will be used for general corporate purposes. The Bonds were placed with a consortium of Swedish institutional investors.
Furthermore, BICO announces its intention to repay its existing convertible bonds, of which SEK 1,008m is currently outstanding, at their final maturity on March 19, 2026.
"The past years, we have taken several actions to strengthen our balance sheet and liquidity. We are already in a position to repay our existing convertible bonds maturing in March 2026. The new capital raise will further enhance our financial flexibility and provide a meaningful operational buffer. This puts us in a position to support further growth and capture a market recovery, while allowing us to navigate ongoing macroeconomic uncertainty. The transaction also serves as a clear testament to the capital markets' continued confidence in BICO." says Maria Forss, President and CEO of BICO.
DNB Carnegie acted as Sole Bookrunner in connection with the issuance of the Bonds. Advokatfirman Cederquist acted as legal advisor to BICO and Roschier Advokatbyrå as legal advisor to DNB Carnegie.
For further information, please contact:Maria Forss, President & CEO, BICO Group ABPhone: EA Elisabeth Lindell +46 76 173 40 59E-mail: [email protected]
Jacob Thordenberg, Chief Financial Officer, BICO Group ABPhone: +46 73 534 88 84E-mail: [email protected]
This information is information that BICO Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-01-28 17:12 CET.
About BICOBICO is a lab automation partner and provider of selected workflows to pharma and biotech. With 48,000+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies, and have been cited in over 10,900 publications. Operating through two business areas - Lab Automation and Life Science Solutions - BICO strives towards the vision to enable and automate the life science lab of the future. BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com
AttachmentsBICO Group AB (publ) has successfully issued senior secured bonds